Extended Spectrum β-Lactamase: Tackling Antibiotic Resistance and Overcoming Treatment Challenges

Journal Title: International Journal of Current Science Research and Review - Year 2024, Vol 7, Issue 10

Abstract

Antibiotics, also known as antibacterials, kill or inhibit bacterial growth but are ineffective against viruses, fungi, or parasites, often leading to misuse. They are categorized by molecular structure, mode of action, and spectrum of activity. Antimicrobial Resistance (AMR) occurs when pathogens no longer respond to antimicrobial drugs, arising naturally or through acquisition. Resistance mechanisms include enzymatic (most common), genetic and physical. Bacteria produce various β-lactamases, such as Extended Spectrum β-lactamases (ESBLs), AmpC enzymes, and carbapenemase to exert resistance to Beta-Lactam (βL) class of antibiotics. ESBL families include TEM, SHV, and CTX-M, with E. coli being the most prevalent host. Any Gram-Negative Bacteria (GNB) can be an ESBL producer, but most common ones are the Enterobacteriaceae including Escherichia coli, Klebsiella pneumoniae, Klebsiella oxytoca and Proteus mirabilis. ESBL-producing Enterobacteriaceae (ESBL-E) resist penicillin, aztreonam, and cephalosporins except cephamycins and carbapenems, posing a significant public health risk. Genetic resistance mechanisms involve random mutations and horizontal gene transfer through either of the following processes namely conjugation, transformation, transduction. Physical mechanisms include efflux pump production and decreased porin channels. In some microbiological laboratories, ESBL production are often not determined, rather resistance based on MIC values to third generation Cephalosporins are considered as resistance due to ESBL production. Antibiotic use in agriculture and medicine has increased Multi-drug resistant (MDR) ESBL-producing E. coli and evidenced in retail meat and among meat shop employees. Community-acquired ESBL-E infections are a growing concern, with hospital transmission primarily occurring among patients sharing rooms with ESBL carriers. Empirical and definitive therapies for ESBL-E infections must be adjusted based on Antibiotic Susceptibility Testing (AST). The MERINO trial identified urinary tract infections as the most common source of ESBL-E bacteremia, with E. coli being predominant. For critically ill patients with non-urinary tract infections, Meropenem or Imipenem-cilastatin are recommended. For uncomplicated UTIs, Nitrofurantoin, Cotrimoxazole, and Piperacillin-Tazobactam (Pip-Taz) are effective, while Cotrimoxazole, Fluoroquinolones, and Ceftolozane-tazobactam are suitable for complicated UTIs. New β-lactamase inhibitors like avibactam, vaborbactam, and relebactam are promising for treatment. Misuse of antibiotics, such as inappropriate dosing and duration, contributes to AMR, a growing global challenge. Deaths from AMR, estimated at 1.27 million in 2019, could reach 10 million by 2050. ESBLs drive the use of broad-spectrum antibiotics, accelerating resistance development. Inadequate therapy exacerbates infections, leading to prolonged hospital stays, complications, and increased mortality. Balancing new drug development with resistance emergence is crucial to combat AMR.

Authors and Affiliations

Leena Muppa, Vaishnavi Velmani , Nandhani N, Vincy Santhana Sophia B, Sriram Radhakrishnan, Bala Abirami M,

Keywords

Related Articles

Various Analytical Methods for Analysis of Sitagliptin – A Review

Sitagliptin is a dipeptidyl- peptidase inhibitor used to treat high blood sugar levels caused by type2 diabetes. Absorption of Sitagliptin is 87% orally bioavailable and taking it with or without food does not affect its...

The Influence of Expertise, Time of Assignment and Audit Stages on the Audit Quality of Internal Government Supervisory Apparatus (APIP) at Inspektorat throughout Aceh

The purpose of this research is to determine the influence of APIP’s expertise, APIP’s time of assignment and audit stages, namely the planning stage, implementation or supervision stage, and reporting stage on audit qua...

Employer Branding to Improve Employee Loyalty after a Business Merger in PT Pelindo Terminal Petikemas

In today’s world, solid employer branding is important for any company or organization. Ambler & Barrow (1996) defined employer branding as the process of building and promoting a company’s reputation as an employer. Ily...

Financial Dynamics of Listed Banks in Pakistan: Exploring the Interplay between Cost-Income Ratio, Capital Adequacy, and Performance Metrics

This study delves into the relationship between the Cost-Income Ratio, Capital Adequacy, and the performance of listed banks in Pakistan. Drawing data from 2014 to 2022 annual reports, the Generalized Method of Moments (...

A Case of FIBROADENOMA Cured with Individualized Homoeopathic Medicine- Evidence Based Homoeopathy

Introduction: Fibro-adenomas are the most common benign tumor of female breast having distinct clinical and Histopathological findings. This case report of fibroadenoma highlights clinical presentation along with proper...

Download PDF file
  • EP ID EP749679
  • DOI 10.47191/ijcsrr/V7-i10-64
  • Views 24
  • Downloads 0

How To Cite

Leena Muppa, Vaishnavi Velmani, Nandhani N, Vincy Santhana Sophia B, Sriram Radhakrishnan, Bala Abirami M, (2024). Extended Spectrum β-Lactamase: Tackling Antibiotic Resistance and Overcoming Treatment Challenges. International Journal of Current Science Research and Review, 7(10), -. https://europub.co.uk/articles/-A-749679